Condition 1: HEART FAILURE. Condition 2: DIABETES. Heart failure Diabetes mellitus due to underlying condition
Conditions
Interventions
Intervention 1: Intervention group:Spironolactone tablets, 25 mg daily, are prescribed to the patient after daily tests are taken. Then, after 1 week, if tolerated and the tests are normal, the dose i
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: over age of 18 years EF < 50% Patients with diabetes on oral medication or pre diabetes Not using mineralocorticoid antagonist drugs
Exclusion criteria
Exclusion criteria: Age less than 18 years old paitents with chronic lung, liver and kidney diseases at the same time pregnancy Taking insulin at the same time History of complications with sprinolactone or eplerenone Cr > 2 the patient is not able to take medicines orally
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin A1C. Timepoint: intial - after 4 month. Method of measurement: A venous blood sample was taken from the patient by a laboratory technician at Rasoul Akram Hospital.;Fasting Blood Suger. Timepoint: intial - after 4 month after startig use of the drug. Method of measurement: A venous blood sample was taken from the patient by a laboratory technician at Rasoul Akram Hospital.;Left ventricular ejection function. Timepoint: intial - after 4 month after startig use of the drug. Method of measurement: Echocardiography.;Brain natriuretic peptide. Timepoint: intial - after 4 month after startig use of the drug. Method of measurement: A venous blood sample was taken from the patient by a laboratory technician at Rasoul Akram Hospital. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count. Timepoint: intial - After 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Blood Urea Nitrogen. Timepoint: intial- after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Creatinin. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Sodium. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Potassium. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Triglyceride. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Low density lipoprotein. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;High density lipoprotein. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Cholestrol. Timepoint: intial - after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician.;Troponin. Timepoint: initial -after 4 month starting the use of drug. Method of measurement: A venous sample was taken from the patient by a laboratory technician. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh vahmani
Iran University of Medical Sciences
Outcome results
None listed